HeartBeam (Nasdaq:BEAT) today announced that a study of its synthesized 12-lead electrocardiogram (ECG) met its clinical ...

The study evaluated the mean difference in ECG intervals and amplitudes between HeartBeam's synthesized 12-lead ECG and simultaneously collected standard 12-lead ECG that are important in assessing ...

Milestone results formed the basis of HeartBeam’s 12-lead ECG synthesis software application submitted to FDA in January 2025 HeartBeam, Inc., (NASDAQ: BEAT), a medical technology company ...

today announced that its groundbreaking synthesized 12-lead electrocardiogram (ECG) successfully met the clinical endpoints in the VALID-ECG pivotal study. Thomas Deering, M.D., of Piedmont Heart ...

The purpose of this study was to evaluate whether the 12-lead ECG could be substituted by ECG sets with a limited number of leads. Materials and methods: The performance of three ECG systems (ie ...

Milestone results formed the basis of HeartBeam’s 12-lead ECG synthesis software application submitted to FDA in January 2025 SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc., (NASDAQ: BEAT), a ...

This is the offical code repository accompanying our paper on Self-supervised representation learning from 12-lead ECG data. For a detailed description of technical details and experimental results, ...

Methods: We propose a conditional Variational Autoencoder (cVAE) framework to generate realistic, subject-specific 12-lead ECGs by incorporating demographic metadata, anatomical heart features, and ...

Be among those who shape the future with knowledge. Uncover exclusive stories that captivate your mind and heart with our FREE 14-day subscription trial. Dive into a world of inspiration, learning, ...